{"brief_title": "A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C", "brief_summary": "This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.", "condition": "Hepatitis C", "intervention_type": "Drug", "intervention_name": "Ribavirin", "criteria": "Major Inclusion Criteria: - Have a clinical diagnosis of chronic HEP C established on the basis of detectable viral load, as measured by a serum HCV RNA test during the screening period. - Have previously failed to respond to treatment with any interferon alfa (IFNa) product - Have compensated liver disease with the following minimum criteria: white blood cell count > 3,000/mm3, absolute neutrophil count (ANC) > 2,000/mm3, platelets > 125,000/mm3, and hemoglobin (Hb) > 13 g/dL for males or > 12 g/dL for females. Major Exclusion Criteria: - Evidence of decompensated cirrhosis or portal hypertension. - Pregnant or lactating female. - History of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study. - A current drug or alcohol addiction", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00097435.xml"}